China's National Medical Products Administration approved Tasly Pharmaceutical's (SHA:600535) application to conduct clinical trials on a drug for recurrent glioblastoma, according to a Shanghai Stock Exchange filing on Saturday.
The P134 cell injection, which was developed by the pharmaceutical company and the Beijing Neurosurgical Institute, will undergo phase 1 trials for patients with the condition.
The pharmaceutical company invested 49.6 million yuan into the research and development of the drug, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments